[
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO3rd. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62, 2569–2581, 2010.10.1002/art.27584
]Search in Google Scholar
[
American College of Rheumatology Subcommittee on Rheumatoid Arthritis G Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46, 328–146, 2002.10.1002/art.10148
]Search in Google Scholar
[
Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 20, S152–S157, 2002.
]Search in Google Scholar
[
Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 18, 121–139, 2004.10.2165/00063030-200418020-00005
]Search in Google Scholar
[
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343, 1586–1593, 2000.10.1056/NEJM200011303432201
]Search in Google Scholar
[
Benham H, Nel HJ, Law SC, Mehdi AM, Street S, Ramnoruth N. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients. Sci Transl Med 7, 87–90, 2015.10.1126/scitranslmed.aaa9301
]Search in Google Scholar
[
Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatol Treat 18, 76–83, 2007.10.1080/09546630601121086
]Search in Google Scholar
[
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54, 26–37, 2006.10.1002/art.21519
]Search in Google Scholar
[
Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41, 2196–2204, 1998.10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2
]Search in Google Scholar
[
Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 70, 1542–1549, 2011.10.1136/ard.2010.146225
]Search in Google Scholar
[
Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451–460, 2013a.10.1016/S0140-6736(12)61424-X
]Search in Google Scholar
[
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72, 517–524, 2013b.10.1136/annrheumdis-2011-201244
]Search in Google Scholar
[
Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 6, 225–230, 1995.
]Search in Google Scholar
[
Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50, 552–562, 2011.10.1093/rheumatology/keq343
]Search in Google Scholar
[
Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344, 907–916, 2001.10.1056/NEJM200103223441207
]Search in Google Scholar
[
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54, 2793–2806, 2006.10.1002/art.22025
]Search in Google Scholar
[
Congreve S, Faris Elias RF, Tidestav G, Zafranian V. Antibody drug conjugates (ADC): Current status and mapping of ADCs in clinical programs 2018.
]Search in Google Scholar
[
Cranwell-Bruce LA. Biological disease modifying anti-rheumatic drugs. Medsurg Nurs 20, 147–152, 2011.
]Search in Google Scholar
[
Danila MI, Hughes LB, Bridges SLJr. Pharmacogenetics of etanercept in rheumatoid arthritis. Pharnacogenomics 9, 1011–1015, 2008.10.2217/14622416.9.8.1011
]Search in Google Scholar
[
Dariushnejad H, Farajnia S, Zargami N, Khosroshahi SA, Rahbarnia L. Dsbc chaperone mediated soluble expression of human TNF-α in E. coli. Minerva Biotecnologia 30, 14–21, 2018.10.23736/S1120-4826.17.02299-6
]Search in Google Scholar
[
Dariushnejad H, Farajnia S, Zarghami N, Aria M, Tanomand A Effect of DnaK/DnaJ/GrpE and DsbC Chaperons on Periplasmic Expression of Fab Antibody by E. coli SEC Pathway. Int J Pept Res Ther 25, 67–74, 2019.10.1007/s10989-017-9637-x
]Search in Google Scholar
[
Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19, 22–25, 1992.
]Search in Google Scholar
[
Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 359, 540–541, 2002.10.1016/S0140-6736(02)07718-8
]Search in Google Scholar
[
Dominguez-Mozo MI, Perez-Perez S, Villar LM, Oliver-Martos B, Villarrubia N, Matesanz F, Ortega-Madueno I. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Sci Rep 10, 14244, 2020.10.1038/s41598-020-71283-5745568932859922
]Search in Google Scholar
[
Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 72, 43–50, 2013.10.1136/annrheumdis-2011-201282355122322562983
]Search in Google Scholar
[
Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350, 2572–2581, 2004.10.1056/NEJMoa032534
]Search in Google Scholar
[
Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48, 3013–3022, 2003.10.1002/art.11301
]Search in Google Scholar
[
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36, 1681–1690, 1993.10.1002/art.1780361206
]Search in Google Scholar
[
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105–1110, 1994a.10.1016/S0140-6736(94)90628-9
]Search in Google Scholar
[
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344, 1125–1127, 1994b.10.1016/S0140-6736(94)90632-7
]Search in Google Scholar
[
Emery P, Keystone E, Tony HP, Cantagrel A, Van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67, 1516–1523, 2008.10.1136/ard.2008.092932381114918625622
]Search in Google Scholar
[
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA. Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60, 2272–2283, 2009.10.1002/art.2463819644849
]Search in Google Scholar
[
Farajnia S, Ghorbanzadeh V, Dariushnejad H. Effect of molecular chaperone on the soluble expression of recombinant fab fragment in E. coli. Int J Pept Res Ther 26, 251–258, 2020.10.1007/s10989-019-09833-3
]Search in Google Scholar
[
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 423, 356–361, 2003.10.1038/nature0166112748655
]Search in Google Scholar
[
Fleischmann R, Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol Interv 6, 310–318, 2003.10.1124/mi.3.6.31014993463
]Search in Google Scholar
[
Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48, 927–934, 2003.10.1002/art.1087012687534
]Search in Google Scholar
[
Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 68, 805–811, 2009.10.1136/ard.2008.099291267455519015206
]Search in Google Scholar
[
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367, 495–507, 2012.10.1056/NEJMoa110907122873530
]Search in Google Scholar
[
Garrido-Mesa N, Zarzuelo A, Galvez J Minocycline: far beyond an antibiotic. Br J Pharmacol 169, 337–352, 2013.10.1111/bph.12139365166023441623
]Search in Google Scholar
[
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. New England Journal of Medicine 353, 1114–1123, 2005.10.1056/NEJMoa05052416162882
]Search in Google Scholar
[
Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72, 863–869, 2013.10.1136/annrheumdis-2012-20160122730366
]Search in Google Scholar
[
Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S. A phase II randomized study of subcutaneous ixekizumab, an anti–interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 66, 1693–1704, 2014.10.1002/art.3861724623718
]Search in Google Scholar
[
Goel N, Stephens S. Certolizumab pegol. MAbs 2, 137–147, 2010.10.4161/mabs.2.2.11271284023220190560
]Search in Google Scholar
[
Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacol Res 64, 610–613, 2011.10.1016/j.phrs.2011.06.01021723947
]Search in Google Scholar
[
Harmse L, Reuter H. An overview of the biological disease modifying drugs available for arthritic conditions in South Africa. South African Family Practice 58, 6–10, 2016.10.4102/safp.v58i6.4595
]Search in Google Scholar
[
Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 73, 1626–1634, 2014.10.1136/annrheumdis-2013-204405414541824297381
]Search in Google Scholar
[
Ishii T, Munakata Y, Kajiwara Y, Takahashi M, Anwar Y, Paccaly F, Kovalenko P, Parrino J, Boyapati A, Xu C. AB0472 Pharmacodynamic effect and safety of single-dose sarilumab sc or tocilizumab iv or sc in patients with rheumatoid arthritis (RA). Ann Rheum Dis 77, 1397–1398, 2018.10.1136/annrheumdis-2018-eular.1375
]Search in Google Scholar
[
Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 3, 81–89, 2010.10.4137/CMAMD.S4864301889321234291
]Search in Google Scholar
[
Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69, 88–96, 2010.10.1136/ard.2008.105197374751919297346
]Search in Google Scholar
[
Jurgens M, Jacobs J, Bijlsma J. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol 25, 523–533, 2011.10.1016/j.berh.2011.10.00622137922
]Search in Google Scholar
[
Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 58, 170–172, 1999.10.1136/ard.58.2008.i70176658210577977
]Search in Google Scholar
[
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400–1411, 2004.10.1002/art.2021715146409
]Search in Google Scholar
[
Keystone E, Heijde DV, Mason Jr D, Landewe R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two–week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58, 3319–3329, 2008.10.1002/art.2396418975346
]Search in Google Scholar
[
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Miranda PC. Golimumab, a human antibody to TNF-αgiven by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 68, 789–796, 2009.10.1136/ard.2008.099010267454919066176
]Search in Google Scholar
[
Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, Chung C, Wong P, Lehane PB, Tyrrell H. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 39, 2238–2246, 2012.10.3899/jrheum.12057323027887
]Search in Google Scholar
[
Kloppenburg M, Terwiel JP, Mallee C, Breedveld FC, Dijkmans BA Minocycline in active rheumatoid arthritis. A placebo-controlled trial. Ann N Y Acad Sci 732, 422–423 1994.10.1111/j.1749-6632.1994.tb24773.x
]Search in Google Scholar
[
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, Ghrayeb J. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30, 1443–1453, 1993.10.1016/0161-5890(93)90106-L
]Search in Google Scholar
[
Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. Journal of Bone Miner Res 11, 88–95, 1996.10.1002/jbmr.5650110113
]Search in Google Scholar
[
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349, 1907–1915, 2003.10.1056/NEJMoa035075
]Search in Google Scholar
[
Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol 156, 486–491, 2007.10.1111/j.1365-2133.2007.07682.x
]Search in Google Scholar
[
Lundkvist M, Engdahl E, Holmen C, Moverare R, Olsson T, Hillert J, Fogdell-Hahn A. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler 19, 757–764, 2013.10.1177/1352458512462920
]Search in Google Scholar
[
Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog EW, Charles PJ, Taylor PC, Feldmann MA. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 144, 195–223, 1995.10.1111/j.1600-065X.1995.tb00070.x
]Search in Google Scholar
[
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939, 1999.10.1016/S0140-6736(99)05246-0
]Search in Google Scholar
[
Martin DA, Churchill M, Flores-Suarez LF, Cardiel MH, Wallace D, Martin R, Phillips K, Kaine JL, Dong H, Salinger D, Stevens E. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 15, R164, 2013.10.1186/ar4347397912524286136
]Search in Google Scholar
[
Mattey DL, Hutchinson D, Dawes PT, Nixon NB, Clarke S, Fisher J, Brownfield A, Alldersea J, Fryer AA, Strange RC. Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus. Arthritis Rheum 46, 640–646, 2002.10.1002/art.1017411920399
]Search in Google Scholar
[
Mazumdar S, Greenwald D. Golimumab. Mabs 1, 422–431, 2009.10.4161/mabs.1.5.9286275949120065639
]Search in Google Scholar
[
McDonnell J, Hoerrner LA, Lark MW, Harper C, Dey T, Lobner J, Eiermann G, Kazazis D, Singer II, Moore VL. Recombinant human interleukin-1 β–induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis Rheum 35, 799–805, 1992.10.1002/art.17803507141320383
]Search in Google Scholar
[
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205–2219, 2011.10.1056/NEJMra100496522150039
]Search in Google Scholar
[
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16, 2825–2833, 1998.10.1200/JCO.1998.16.8.28259704735
]Search in Google Scholar
[
Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors. J Rheumatol 37, 917–927, 2010.10.3899/jrheum.09044220194448
]Search in Google Scholar
[
Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 71, 1183–1189, 2012.10.1136/annrheumdis-2011-20070422328739
]Search in Google Scholar
[
Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani HA, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151, 1548–1561, 1993.10.4049/jimmunol.151.3.1548
]Search in Google Scholar
[
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 130, 478–486, 1999.10.7326/0003-4819-130-6-199903160-0000410075615
]Search in Google Scholar
[
Neovius M, Simard JF, Askling J; ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 70, 624–629, 2011.10.1136/ard.2010.13337121149495
]Search in Google Scholar
[
Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, Van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63, 545–555, 2011.10.1002/art.3012821280009
]Search in Google Scholar
[
O’Dell JR, Gilg J, Palmer W, Haire C, Klassen L, Moore G. Pneumococcal vaccine in rheumatoid arthritis. J Clin Rheumatol 2, 59–63, 1996.10.1097/00124743-199604000-0000119078031
]Search in Google Scholar
[
Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol 30, 1182–1190, 2003.
]Search in Google Scholar
[
Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. J Rheumatol 34, 57–63, 2007.
]Search in Google Scholar
[
Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-α–mediated joint destruction. The J Clin Invest 110, 1419–1427, 2002.10.1172/JCI0215582
]Search in Google Scholar
[
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435–445, 1994.10.1182/blood.V83.2.435.bloodjournal832435
]Search in Google Scholar
[
Rudan I, Sidhu S, Papana A, Meng SJ, Xin–Wei Y, Wang W, Campbell-Page RM, Demaio AR, Nair H, Sridhar D, Theodoratou E. Prevalence of rheumatoid arthritis in low–and middle–income countries: A systematic review and analysis. J Glob Health 5, 010409, 2015.
]Search in Google Scholar
[
Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67, 1096–1103, 2008.10.1136/ard.2007.080002
]Search in Google Scholar
[
Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1, 1108–1111, 1987.10.1016/S0140-6736(87)91672-2
]Search in Google Scholar
[
Scott LJ. Sarilumab: first global approval. Drugs 77, 705–712, 2017.10.1007/s40265-017-0724-2
]Search in Google Scholar
[
Sell S. Immunology, Immunopathology and Immunity. Elsevier, the 4th edition, 1987.
]Search in Google Scholar
[
Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G, Tam S, Sague S, Wang D. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs 2, 428–439, 2010.10.4161/mabs.12304
]Search in Google Scholar
[
Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 67, 280–309 2015.10.1124/pr.114.009639
]Search in Google Scholar
[
Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 23, 288–292, 2011.10.1097/BOR.0b013e328344f2e4
]Search in Google Scholar
[
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges Jr SL. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64, 625–639, 2012.10.1002/acr.21641
]Search in Google Scholar
[
Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R, European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, andomised, multicentre trial. European Leflunomide Study Group. Lancet 353, 259–266, 1999.10.1016/S0140-6736(98)09403-3
]Search in Google Scholar
[
Smolen JS, Steiner G Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2, 473–488, 2003.10.1038/nrd110912776222
]Search in Google Scholar
[
Smolen JO, Landewe RB, Mease PH, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. AnnRheum Dis 68, 797–804, 2009a.10.1136/ard.2008.101659
]Search in Google Scholar
[
Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multi-centre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221, 2009b.10.1016/S0140-6736(09)60506-7
]Search in Google Scholar
[
Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73, 1616–1625, 2014.10.1136/annrheumdis-2013-205137414544624699939
]Search in Google Scholar
[
St Clair EW, Van Der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, DeWoody K. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50, 3432–3443, 2004.10.1002/art.2056815529377
]Search in Google Scholar
[
Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol, 30, 2112–2122, 2003.
]Search in Google Scholar
[
Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S. Efalizumab. Expert Opin Drug Saf 10, 239–251, 2011.10.1517/14740338.2011.52492521214420
]Search in Google Scholar
[
Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NM, Kameda H. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther 21, 79, 2019.10.1186/s13075-019-1856-4642565830894208
]Search in Google Scholar
[
Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, Duncan H. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Inter Med 122, 81–89, 1995.10.7326/0003-4819-122-2-199501150-000017993000
]Search in Google Scholar
[
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117, 244–279, 2008.10.1016/j.pharmthera.2007.10.00118155297
]Search in Google Scholar
[
van Beuningen HM, Arntz OJ, van den Berg WB. In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum 34, 606–615, 1991.10.1002/art.17803405132025312
]Search in Google Scholar
[
van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 38, 164–172, 1995.10.1002/art.17803802047848306
]Search in Google Scholar
[
Van Der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzova D. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 559–570, 2013.10.1002/art.3781623348607
]Search in Google Scholar
[
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 508–519, 2012.10.1056/NEJMoa111207222873531
]Search in Google Scholar
[
Venkiteshwaran A. Tocilizumab. MAbs 1, 432–438, 2009.10.4161/mabs.1.5.9497275949220065633
]Search in Google Scholar
[
Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139, W58–W63, 2003.10.7326/0003-4819-139-3-200308050-00021-w412899609
]Search in Google Scholar
[
Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today 15, 40–56, 2010.10.1016/j.drudis.2009.10.00919879957
]Search in Google Scholar
[
Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208, 228–251, 2005.10.1111/j.0105-2896.2005.00338.x16313352
]Search in Google Scholar
[
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48, 35–45, 2003.10.1002/art.1069712528101
]Search in Google Scholar
[
Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 54, 2807–2816, 2006.10.1002/art.2207016947384
]Search in Google Scholar
[
Weir N, Athwal D, Brown D, Foulkes R, Kollias G, Nesbitt A, Popplewell A, Spitali M, Stephens S. A new generation of high-affinity humanized PEGylated Fab[acute accent] fragment anti-tumor necrosis factor-[alpha] monoclonal antibodies. Clin Pract 3, 535–539, 2006.10.1586/14750708.3.4.535
]Search in Google Scholar
[
Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68, 1870–1877, 2009.10.1136/ard.2008.101121277010419124524
]Search in Google Scholar
[
Zernicke RF, Wohl GR, Greenwald RA, Moak SA, Leng W, Golub LM. Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. J Rheumatol 24, 1324–1331, 1997.
]Search in Google Scholar
[
Xu LX, Kukita T, Nakano Y, Yu H, Hotokebuchi T, Kuratani T, Iijima T, Koga T. Osteoclasts in normal and adjuvant arthritis bone tissues express the mRNA for both type I and II interleukin-1 receptors. Lab Invest 75, 677–687, 1996.
]Search in Google Scholar
